2020年-2021年山东中医药大学附属医院冠心病治疗费用分析  

Analysis of Coronary Heart Disease Treatment Costs in a Tertiary Hospital of Shandong Province from 2020 to 2021

作　　者：刘益成[1] 袁杰[1] 张宇航 

机构地区：[1]山东中医药大学,济南250355

出　　处：《中国医疗保险》2022年第5期92-94,共3页China Health Insurance

摘　　要：目的:分析研究冠心病患者的治疗费用及构成比例,探索可减少患者治疗费用支出的医疗服务。方法:选取2020年—2021年山东中医药大学附属医院收治的4000例冠心病患者为研究对象,采用单因素与多元回归分析,研究患者的治疗费用和影响因素。结果:冠心病患者的人均治疗费用为9000元,占总费用比例较高的是医疗服务费、药费和诊断费,高龄、有并发症且住院天数较长会使治疗费用增多。结论:冠心病患者治疗费用中占比最高的是医疗服务费用,应根据患者的实际情况合理用药,并加强对药物使用的监管,优化治疗费用结果。Objective:The paper is to study and analyze the treatment costs and structure of patients with coronary heart disease,and to detect medical service to reduce the treatment costs.Methods:A total of 4000 patients with coronary heart disease admitted to the Affiliated Hospital of Shandong University of Traditional Chinese Medicine from 2020 to 2021 were selected as subjects.Univariate and multiple regression analysis were performed on the treatment cost.Results:The per capita treatment cost of patients was 9,000 yuan,and the proportion of the total cost was ordered as medical service fee,drug fee and diagnosis fee.The results showed that the age,complications and long hospital stay were the factors increasing hospitalization cost.Conclusion:The highest proportion of treatment cost of patients with coronary heart disease is medical service fee.Drugs should be used rationally,and supervision of drug use should be strengthened to optimize the treatment cost and results.

关 键 词：冠心病 治疗费用 影响因素 

分 类 号：F840.684[经济管理—保险] C913.7[社会学]